Compare · PFE vs SBFM
PFE vs SBFM
Side-by-side comparison of Pfizer Inc. (PFE) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $304.95B.
- Over the past year, PFE is up 17.1% and SBFM is down 30.8% - PFE leads by 47.9 points.
- PFE has been more active in the news (10 items in the past 4 weeks vs 3 for SBFM).
- PFE has more recent analyst coverage (25 ratings vs 0 for SBFM).
- Company
- Pfizer Inc.
- Sunshine Biopharma Inc.
- Price
- $26.98+1.20%
- $1.00-0.99%
- Market cap
- $304.95B
- -
- 1M return
- -1.21%
- -1.96%
- 1Y return
- +17.13%
- -30.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 0
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sunshine Biopharma Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest SBFM
- SEC Form 4 filed by Natan David
- Sunshine Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
- SEC Form 10-K filed by Sunshine Biopharma Inc.
- SEC Form NT 10-K filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEF 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form PRE 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update